Risk of De Novo Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis Treated With IL ‐ 17A Inhibitors: A Population‐Based Study
Alimentary Pharmacology & Therapeutics · 2025
DOI: 10.1111/apt.70139 ↗At a glance
Journal article in Alimentary Pharmacology & Therapeutics, 2025. Written by Saqr Alsakarneh and 5 co-authors. Institution: Department of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA. Major MEDLINE topics: Arthritis, Psoriatic, Interleukin-17, Inflammatory Bowel Diseases, Psoriasis. Cited 21 times so far (Crossref); 10 references.
Abstract (original language)
IL‐17 inhibitors effectively treat psoriasis and psoriatic arthritis but may increase the risk of inflammatory bowel disease (IBD). We assessed their association with IBD compared to apremilast. Utilising the TriNetX database, we analysed patients with psoriasis or ankylosing spondylitis initiating IL‐17 inhibitors or apremilast. We used propensity score matching and Cox models to estimate IBD risk. Among 13,216 matched patients per group, 142 developed IBD with IL‐17 inhibitors versus 60 with apremilast (aHR = 2.50, 95% CI: 1.85–3.39). IL‐17 inhibitors increase IBD risk, necessitating careful patient selection and monitoring.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA.
- Department of Medicine, Allegheny Health Network, Pittsburgh, Pennsylvania, USA.
- Department of Medicine, Henry Ford Hospital, Detroit, Michigan, USA.
- Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida, USA.
ORCID profiles: Saqr Alsakarneh, Omar Al Ta'ani
Cite
APA
Alsakarneh, S., Al Ta'ani, O., Aburumman, R., Mikhail, I., Hashash, J. G., & Farraye, F. A. (2025). Risk of De Novo Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis Treated With IL ‐ 17A Inhibitors: A Population‐Based Study. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70139
Vancouver
Alsakarneh S, Al Ta'ani O, Aburumman R, Mikhail I, Hashash JG, Farraye FA. Risk of De Novo Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis Treated With IL ‐ 17A Inhibitors: A Population‐Based Study. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70139
BibTeX
@article{Alsakarneh2025,
author = {Alsakarneh, Saqr and Al Ta'ani, Omar and Aburumman, Razan and Mikhail, Inas and Hashash, Jana G and Farraye, Francis A},
title = {Risk of De Novo Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis Treated With IL ‐ 17A Inhibitors: A Population‐Based Study},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
doi = {10.1111/apt.70139}
}
EUVIMED